Slaoui will return $3.86M to GlaxoSmithKline after his dismissal for sexual harassment Senate narrowly votes to get rid of COVID-19 national emergency Eli Lilly extends winning streak as it keeps the TV ad spend throne holding off Regeneron's Dupixent Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial Fitbit recalls nearly 1M Ionic smartwatches in US due to burn hazard vTv CEO resigns 4 months into job after slashing workforce, refocusing pipeline 3 in 4 infusion pumps vulnerable to cyberattacks: study Evolus' has something to smile about as neurotoxin Jeuveau's 2021 sales swell 76% BeiGene's hematology CMO resigns in wake of solid tumor switch Allscripts sells hospital business unit in $700M deal with Constellation subsidiary Fierce Pharma Asia—J&J, Legend's CAR-T nod; Biocon's $3.3B Viatris biosimilar buy; Sanofi-Adagene tie-up Dry AMD treatment developer LumiThera nets retinal diagnostic maker Diopsys Featured Story | By Kevin Dunleavy Former Operation Warp Speed chief Moncef Slaoui, who GlaxoSmithKline fired last year because of a sexual harassment claim, is returning $3.86 million to the company, according to its annual executive compensation report. read more |
| |
|---|
|
Top Stories By Robert King The Senate narrowly passed a resolution calling for an end to the COVID-19 national emergency, which garnered a White House veto threat. read more By Ben Adams It’s as things were in January for the first two spots of pharma’s top TV ad spenders. In February again, Lilly’s diabetes drug Trulicity came in at No. 1 with a hefty $45.8 million spend, while Regeneron and Sanofi’s Dupixent sat in second. read more By Nick Paul Taylor Shionogi’s COVID-19 vaccine candidate has held its own against Pfizer’s Comirnaty in a study of the effect of booster shots on antibody levels, offering the company encouragement as it barrels toward a filing for approval of S-268019 in Japan. read more By Heather Landi Fitbit is voluntarily recalling about 1.7 million Ionic smartwatches sold globally because the product's lithium-ion battery can overheat, posing a burn hazard. read more By Kyle LaHucik Deepa Prasad has resigned as CEO and president of vTv Therapeutics just four months into the job after having prioritized the biotech's pipeline to focus on Type 1 diabetes and having laid off 65% of the company in December. read more By Conor Hale Palo Alto Networks used scans of more than 200,000 smart infusion pumps and discovered that 75% had at least one known and publicly documented security gaps. read more By Fraiser Kansteiner Evolus’ Jeuveau garnered $34.7 million in the fourth quarter and $99.7 million in full-year 2021 sales, rising more than 76% over the $56.6 million it made in 2020. Evolus credited those gains to boosted sales volume and the med’s higher price point in the U.S. The company also highlighted the success of its beauty-first, millennial-targeted marketing push. read more By Nick Paul Taylor BeiGene’s hematology chief medical officer is hitting the exit. Almost six years after joining BeiGene, Jane Huang has handed in her resignation shortly after the replacement of her solid tumor counterpart. read more By Rebecca Torrence Health IT company Allscripts will sell its hospital and large physician practices business segment to a subsidiary of Constellation Software in a deal worth up to $700 million that's expected to close in the second quarter of 2022. read more By Angus Liu Legend Biotech and Janssen's CAR-T therapy Carvykti has won an FDA go-ahead to challenge Bristol Myers Squibb in multiple myeloma. Biocon Biologics is buying partner Viatris' biosimilars business. Sanofi taps Adagene's "safe" antibody technology in a deal potentially worth $2.5 billion. And more. read more By Conor Hale Diopsys’ equipment measures the electrical responses of the retina, while LumiThera's light-based dry AMD therapy aims to stimulate cellular activity at the back of the eye. read more | 